person · Reporting owner
AYCARDI-FONSECA ERNESTO
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | CMO | March 12, 2020 | March 13, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date March 12, 2020 · Filed March 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.58 · Expires 2030-03-11 | Direct | 65,000 |
Reported balance
After 2020-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-12 · Grant · Acquired 65,000 · Balance 65,000 F1: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2020 Filed Mar 13, 2020 17:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-20-018958 · doc4.xml · derivative · entry 1 AYCARDI-FONSECA ERNESTO · CIK 0001734218 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 18:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-19-050127 · doc4.xml · derivative · entry 1 AYCARDI-FONSECA ERNESTO · CIK 0001734218 · CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2029-09-15 F1 · derivative.exercise_date: Vesting over 36 months, in equal amounts, on the last day of each month. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 16:44 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001171843-18-002118 · formfour.xml · derivative · entry 1 AYCARDI-FONSECA ERNESTO · CIK 0001734218 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2028-03-18 F1 · derivative.exercise_date: Vesting 25% on March 19, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.